OUR MISSION
TechnoGenesys is focused on the commercialization of a novel cancer inhibitor with immune-regulatory activity, (R)-9b or Mahatinib, that overcomes Castration-Resistant Prostate Cancer (CRPCs), Triple Negative Breast Cancer (TNBC), and Non-Small Cell Lung Cancers (NSCLC).
Phase I Clinical Trial, `PHAROS’ is going to start soon (IND#167907)
Clinicaltrials.gov/study/NCT06705686
(R)-9b, a novel small molecule, AR-antagonist
(R)-9b is a small molecule inhibitor that suppresses activity of AR-interacting tyrosine kinase, ACK1 (also known as TNK2). ACK1/AR complex regulates AR and AR-V7 expression. By virtue of ACK1 inhibition, (R)-9b suppresses not only AR (and AR-V7) expression, but also overcomes tumor growth of Castration Resistant Prostate Cancer (CRPC). Significantly, (R)-9b sensitizes Enzalutamide and Abiraterone-resistant prostate cancer, opening a new therapeutic modality for these patients, a critical unmet need.
(R)-9b is a new class of immune modulator
(R)-9b is an UNIQUE molecule with dual-inhibitory activity: it not only acts on cancer cells by acting as an AR-antagonist, but also elicit CD8+ T cells, the host immune response against cancer cells. This dual activity makes this compound an highly effective inhibitor against prostate cancer, drug-resistant breast and lung cancers. This is highly relevant as immune checkpoint blockade (ICB) antibodies have modest response in prostate and breast cancers. Thus, (R)-9b emerged as a new class of dual-action immune modulator that can sensitize these difficult to treat cancers.
Dr. Nupam Mahajan
President & CEO
Dr. Gerald Andriole
Chief Medical Officer
Steve Nemeth
Founder Director
Dr. Mark McLaughlin
Scientific Advisor
Dr. Kiran
Co-founder, Director
Dr. Flaherty
Advisor
Dr.
Director
